Literature DB >> 31100680

Total glucosides of paeony for the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials.

Qi Zheng1, WenCheng Jiang2, XiaoYing Sun3, Tian Ma4, WenBin Xu5, Fang Shen2, HongJin Li3, ShaoQiong Xie2, Bin Li6, Xin Li7.   

Abstract

BACKGROUND: Psoriasis is a common chronic relapsing immune-mediated inflammatory disease, the prevalence of which has increased in recent years. At present, there are many treatment methods available for the condition, but the curative effect is unsatisfactory. HYPOTHESIS/
PURPOSE: This study aimed to evaluate the efficacy, adverse reactions, and recurrence rates of using paeoniflorin capsules for psoriasis treatment. STUDY
DESIGN: systematic review and meta-analysis.
METHODS: Randomized controlled trials comparing total glycosides of paeony (TGP) with other treatments for patients with psoriasis were retrieved by searching EMBASE, MEDLINE, and the Cochrane Central Register of Controlled Trials electronic databases. Cochrane bias risk tool was used to evaluate the quality of randomized controlled trial (RCT) methodology. The primary outcome measure is the effective number. Secondary outcomes included psoriasis area and severity index (PASI), adverse reactions, recurrence, and inflammatory biomarkers.
RESULTS: In all, 30 RCTs with 2,802 participants were included in this meta-analysis. The studies were generally of low methodological quality. Although there was no statistically significant difference between the use of TGP capsule alone and other monotherapies in the treatment of psoriasis (RR: 0.93; 95% CI: 0.76-1.15; p = 0.50), the addition of TGP to other therapies had an advantage over monotherapy with regard to the effective number (RR: 1.31; 95% CI: 1.26-1.37; p < 0.00001), PASI (RR: -3.40; 95% CI: -4.22,-2.57; p < 0.00001), adverse reactions, recurrence rate (RR: 0.42; 95% CI: 0.24-0.74; p = 0.002), and inflammatory inhibition (RR:-12.54; 95% CI: -18.50, -6.59; p < 0.0001).
CONCLUSIONS: TGP can be used to treat psoriasis with reduced adverse reactions and recurrence rates. However, the mechanism of TGP in psoriasis treatment requires to be evaluated further in high-quality, large-sample, and rigorous clinical studies.
Copyright © 2019 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Adverse reactions; Psoriasis; Randomized controlled trials; Total glucosides of paeony

Mesh:

Substances:

Year:  2019        PMID: 31100680     DOI: 10.1016/j.phymed.2019.152940

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  11 in total

1.  Successful treatment of Morbihan disease with total glucosides of paeony: A case report.

Authors:  Li-Feng Zhou; Rong Lu
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

2.  Characteristics of psoriasis vulgaris in China: a prospective cohort study protocol.

Authors:  Ying Luo; Yi Ru; Xiaoying Sun; Yaqiong Zhou; Yingyao Yang; Tian Ma; Rong Xu; Jie Chen; Mi Zhou; Kan Ze; Li Ju; Yanjiao Wang; Qingfeng Yin; Ruiping Wang; Bin Li; Xin Li
Journal:  Ann Transl Med       Date:  2019-11

3.  Oral Taodan granules for mild-to-moderate psoriasis vulgaris: protocol for a randomized, double-blind, multicenter clinical trial.

Authors:  Yi Ru; Xiao-Ning Yan; Su-Qing Yang; Li-Ping Gong; Ling-E Li; Jie Chen; Yi-Ding Zhao; Yue-Peng An; Gang Huang; Jin-Fang Zhang; Qing-Feng Yin; Rui-Ping Wang; Xin Li; Bin Li
Journal:  Ann Transl Med       Date:  2019-09

4.  Efficacy and Safety of Jueyin Granules for Patients with Mild-to-Moderate Psoriasis Vulgaris: Protocol for a Multicenter Randomized Placebo-Controlled Trial.

Authors:  Su Li; Cang Zhang; Hong-Ya Zhang; Meng Zhou; Si-Nong Wang; Rong Xu; Dong-Mei Zhou; Yun-Run Ji; Jing-Jing Lv; Qing-Feng Yin; Rui-Ping Wang; Wei Li; Yan-Ping Liu; Jian-Feng Wang; Bin Li; Xin Li
Journal:  Evid Based Complement Alternat Med       Date:  2020-04-09       Impact factor: 2.629

Review 5.  Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials.

Authors:  Yue Luo; Jiale Chen; Le Kuai; Ying Zhang; Xiaojie Ding; Ying Luo; Yi Ru; Meng Xing; Hongjin Li; Xiaoying Sun; Bin Li; Xin Li
Journal:  Front Pharmacol       Date:  2021-01-22       Impact factor: 5.810

6.  Paeoniflorin suppresses allergic and inflammatory responses by promoting autophagy in rats with urticaria.

Authors:  Jing Guo; Li Peng; Jinhao Zeng; Meiheng Zhang; Feng Xu; Xiaotong Zhang; Qin Wei
Journal:  Exp Ther Med       Date:  2021-04-08       Impact factor: 2.447

7.  Effect of Total Glucosides of Paeony on Imiquimod-Induced Psoriatic Skin Lesions by Regulating VEGF.

Authors:  Yuan Zhang; Xuan Zhou; Ledong Sun
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-12-24

8.  Establishment of Mouse Models of Psoriasis with Blood Stasis Syndrome Complicated with Glucose and Lipid Metabolism Disorders.

Authors:  Ying Luo; Yi Ru; Huaibo Zhao; Liu Liu; Seokgyeong Hong; Xiaoying Sun; Le Kuai; Yi Lu; Meng Xing; Xi Chen; Jiankun Song; Yue Luo; Xiaoya Fei; Yaqiong Zhou; Hongjin Li; Bin Li; Xin Li
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-12       Impact factor: 2.629

9.  Our Choice: study protocol for a randomized controlled trial for optimal implementation of psoriasis treatment by the integration of Chinese and western medicine.

Authors:  Xiaoying Sun; Xiaoyong Zhou; Yuegang Wei; Wenxin Yang; Ning Huang; Yangfeng Ding; Rongyi Hu; Shun Guo; Chunyan Yang; Huilan Weng; Ying Zhang; Xi Chen; Xiaojie Ding; Liu Liu; Qingfeng Yin; Ruiping Wang; Xin Li; Bin Li
Journal:  Trials       Date:  2020-03-30       Impact factor: 2.279

10.  A pharmacokinetics-pharmacodynamics study of single-dose total glucosides of paeony capsule on reducing serum total bile acid in hepatic injury rats.

Authors:  Ninghua Jiang; Bohong Zheng; Yihan Feng; Lei Yin; Yuanrong Liu; Lujing Cao; Ning Zheng; Suxiang Wu; Baoyue Ding; Xuan Huang; Jeffrey Wang; Shuyu Zhan
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.